Celldex Stock Drops Despite Positive Trial Results
Celldex's stock fell more than 20% in premarket trading despite announcing positive results from two late-stage trials for its experimental therapy, barzolvolimab. The drug is being tested as a treatment for urticaria (hives), and the company reported favorable outcomes. The significant drop suggests that investors may have had higher expectations or were concerned about other factors not addressed in the trial results announcement. Celldex is based in New Jersey, and its shares are traded on NASDAQ under the ticker CLDX.
Tickers: $CLDX
Topics: Biotech Clinical Trials Market Reaction